Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
CALCIPOTRIOL BETAMETHASONE
PCO Manufacturing
CALCIPOTRIOL BETAMETHASONE
50/500 Micrograms/g
Ointment
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
_ _ PACKAGE LEAFLET: INFORMATION FOR THE USER DOVOBET ® 50 MICROGRAM/G + 0.5MG/G OINTMENT CALCIPOTRIOL/BETAMETHASONE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Dovobet ® isand what is it used for? 2. Before you use Dovobet ® 3. How to use Dovobet ® 4. Possible side effects 5. How to store Dovobet ® 6. Further Information 1. WHAT DOVOBET IS AND WHAT IS IT USED FOR? Dovobet® ointment is used on the skin to treat plaque psoriasis (psoriasis vulgaris) in adults. Psoriasis is caused by your skin cells being produced too quickly. This causes redness, scaling and thickness of your skin. Dovobet® ointment contains calcipotriol and bethamethasone. Calcipotriol helps to bring the rate of the skin cell growth back to normal and bethamethasone acts to reduce inflammation. 2. BEFORE YOU USE DOVOBET ® DO NOT USE DOVOBET ® If you are allergic (hypersensitive) to calcipotriol, betamethasone or any of the other ingredients in Dovobet® If you have problems with calcium levels in the body ( ask your doctor) If you have certain types of psoriasis: these are erythrodermic, exfoliative and pustular (ask your doctor) AS DOVOBET ® CONTAINS A STRONG STEROID DO NOT USE ON SKIN AFFECTED BY: Infections caused Perskaitykite visą dokumentą
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dovobet 50 microgram/g + 0.5 mg/g ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 50 microgram of Calcipotriol (as monohydrate) and 0.5mg betamethasone (as dipropionate). Excipients with known effect: The product contains butylhydroxytoluene. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ointment. _Product imported from the UK and Portugal:_ Off-white to yellow, ointment. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dovobet ointment should be applied to the affected area once daily. The recommended treatment period is 4 weeks. There is experience with repeated courses of Dovobet up to 52 weeks. If it is necessary to continue or restart treatment after 4 weeks, treatment should be continued after medical review and under regular medical supervision. When using calcipotriol containing medicinal products, the maximum daily dose should not exceed 15 g. The body surface area treated with calcipotriol containing medicinal products should not exceed 30% (see section 4.4). SPECIAL POPULATIONS _Renal and hepatic impairment_ The safety and efficacy of Dovobet ointment in patients with severe renal insufficiency or severe hepatic disorders have not been evaluated. PAEDIATRIC POPULATION The safety and efficacy of Dovobet ointment in children below 18 years have not been established. Currently available data in children aged 12 to 17 years are described in section 4.8 and 5.1 but no recommendation on a posology can be made. METHOD OF ADMINISTRATION Dovobet ointment should be applied to the affected area. In order to achieve optimal Perskaitykite visą dokumentą